Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 9/20 | 0.44 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17130176 | 0.89 | NTRK1 (0.46) | CCNCCDK8NTRK1KCNJ6KCNJ5 | |
| SCHEMBL18925833 | 0.89 | ALDH1A1 (0.51) | CCNCCDK8NTRK1MAPK14MAPK13 | |
| SCHEMBL17112738 | 0.87 | CCNC (0.44) | CCNCCDK8NTRK1KCNJ6KCNJ5 | |
| SCHEMBL17130175 | 0.86 | NTRK1 (0.42) | CCNCCDK8NTRK1KCNJ6KCNJ5 | |
| SCHEMBL17130173 | 0.78 | NTRK1 (0.58) | CCNCCDK8NTRK1KCNJ6KCNJ5 | |
| SCHEMBL17130158 | 0.78 | ALDH1A1 (0.52) | CCNCCDK8NTRK1MAPK14MAPK13 | |
| SCHEMBL17130156 | 0.76 | ALDH1A1 (0.50) | CCNCCDK8NTRK1KCNJ6KCNJ5 | |
| SCHEMBL17130159 | 0.75 | ALDH1A1 (0.47) | CCNCCDK8NTRK1MAPK14MAPK13 | |
| SCHEMBL18694530 | 0.75 | ALDH1A1 (0.48) | CCNCCDK8NTRK1KCNJ6KCNJ5 | |
| SCHEMBL17112724 | 0.72 | NTRK1 (0.48) | CDK8NTRK1KCNJ6KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914736-B2 | TrKA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170158698-A1 | TrKA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158698-A1 | TrKA Kinase Inhibitors, Compositions and Methods Thereof | NGFR, NGF, NTRK2 | CCNC 952/4885CDK8 770/4885NTRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.